Real-world feasibility and safety of neoadjuvant FOLFIRINOX in pancreatic ductal adenocarcinoma: a retrospective single-center study
Soetkin D’Haens, Antoon Billiet, Halit Topal, Baki Topal, Filip Van Herpe, Jeroen Dekervel · 2026
Read Real-world feasibility and safety of neoadjuvant FOLFIRINOX in pancreatic ductal adenocarcinoma: a retrospective single-center study by Soetkin D’Haens, Antoon Billiet, Halit Topal, Baki Topal, Filip Van Herpe, Jeroen Dekervel (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/PMC13350476.txt.
Description
Soetkin D'Haens and co-authors reviewed real-world use of a strong chemotherapy combination before surgery for pancreatic cancer in a 2026 single-centre study. Eighty-one patients with borderline removable or locally advanced tumours received FOLFIRINOX or a softened version between 2020 and 2023.
The median number of cycles delivered was six, and most patients had good fitness scores at entry. The team recorded doses, serious side effects, and why treatment stopped; surgery was the commonest reason, accounting for 45 patients. Pre-surgery chemotherapy is spreading, but its toxicity and delays are real, and honest completion numbers help design fair trials of the strategy.
Catalog record
| CREATOR | Soetkin D’Haens, Antoon Billiet, Halit Topal, Baki Topal, Filip Van Herpe, Jeroen Dekervel |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 35470 |
| LICENSE | https://creativecommons.org/licenses/by/4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |